(HealthDay News) — Pharmacologic treatment of urgency urinary incontinence (UUI) improves sleep quality, according to research published online in Obstetrics & Gynecology.
Qurratul A. Warsi, MBBS, from University of California, San Francisco, and colleagues conducted planned secondary data analysis of sleep outcomes in a previously conducted multicenter, randomized trial of pharmacologic therapy for urgency-predominant incontinence among 645 community-dwelling women. Incontinence symptoms and a sleep assessment were conducted at baseline and 12 weeks.
The researchers found that, at baseline, 57% of women had poor sleep quality (Pittsburgh Sleep Quality Index score of >5). At study follow-up, women randomized to the antimuscarinic group reported a greater decrease in UUI frequency (P<0.001) and diurnal and nocturnal voiding frequency (P<0.05), compared the placebo group. The antimuscarinic group also reported greater improvement in sleep quality (total Pittsburgh Sleep Quality Index score of 0.48; P=0.02), with greater improvement in sleep duration and sleep efficiency subscales (P<0.05). Daytime sleepiness was not affected.
Continue Reading
“Pharmacologic treatment of UUI is associated with decreased incontinence frequency and nocturia and improvement in overall sleep quality, sleep duration, and sleep efficiency,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which provided study medication.
